2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Measurable Residual Disease, Research, Translational Research, Study Population, Human, Adult
PAPER

691 Single-cell sequencing and functional profiling of patient-derived cancer-associated fibroblasts reveal key drivers of CART cell resistance

Omar Gutierrez-Ruiz, PhD, Jennifer Meyer Feigin, BS2, Elizabeth Louise Siegler, PhD3, Panwen Wang, Ph.D., M.S.4, Wannakorn Khopanlert, MD5, Ismail Can, PhD6, Yoh Yamaguchi, MD7, Charles Joseph Kuhlmann, PhD8, Claudia Manriquez-Roman, PhD9, Dominic Ambrosio Skeele10, Ateka Saleh11, Sophia Yael Goldberg12, Sara Foote13, Mehrdad Hefazi Torghabeh, MD14, Brooke L Kimball15, Grace Elizabeth DeFranco, BS16, Long K Mai, BS17, Truc Ngoc Huynh, MS18, R. Leo Sakemura, MD,PhD19, Saad Kenderian, M.B., Ch.B.20
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States

Cancer associated fibroblasts (CAFs) promote tumor progression and suppress anti-tumor activity. CAFs have been identified as drivers of immunotherapy resistance, but their interactions with chimeric antigen receptor T (CART) cells remain poorly understood. Here we generated single-cell atlases and preclinical models of CAFs and the tumor microenvironment (TME) in multiple myeloma (MM) to investigate how CAF heterogeneity and signaling promote CART cell resistance. We validated these findings in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) CAF-CART models to assess whether CAF signaling, subsets, and TME interactions are conserved across hematological and solid tumors.

To elucidate CAF-associated mechanisms of resistance in MM, we first performed single cell sequencing (scRNA-seq) of CD138 negative baseline bone marrows (BMs) from 51,122 cells derived from 8 patients (divided into responders (R, defined as complete response at one year post therapy) and non-responders (NR, defined as progressive disease at one year post therapy) to BCMA-CART cell therapy. We observed significant increases in suppressive CAF (sCAF) markers (FSP-1, FAP, CAIX p<0.001, MME, CD73 p<0.005) in NR and elevated levels of non-suppressive CAF (nCAF) markers (CD90, CD105 p<0.01) in R BMs. CellChat analyses revealed elevated inhibitory CXCL12/CXCR4 CAF-macrophage and CAF-T cell signaling in NR compared to R (p<0.001). In addition, R exhibited greater percentages of nCAFs compared to NR (55% vs 21%, p<0.01). These results indicate that sCAF subsets and signaling are associated with clinical response to BCMA-CART cell therapy.

To study CAF-mediated CART suppression, we co-cultured BCMA-CART cells and BCMA? MM cell lines (OPM2 or MM1S) with patient-derived BM CAFs or WI-38 normal fibroblasts. BCMA-CART cells exhibited decreased proliferation (p<0.005), activation (CD25, CD69 p<0.01), and upregulated inhibitory receptor expression in the presence of CAFs (PD1, LAG3 p<0.001; TIM3 p<0.005). To assess CAF-driven MM progression and BCMA-CART inhibition in vivo, NSG mice were i.v. engrafted with MM cell lines alone or in combination with patient-derived CAFs (1x106 cells, each). BCMA-CART cell treatment (1x106 cells) resulted in total tumor clearance in mice engrafted with MM cells alone while BCMA-CART failed to control tumor growth in MM cell and CAF engrafted mice.

To determine whether MM CAF-immunosuppressive mechanisms extend to solid tumors, we evaluated 316,713 CAFs isolated from 20 CRC and PDAC patient tumors. We first co-cultured patient CAFs with CD3/CD28-bead activated T cells. All CAFs exhibited high FAP expression and 70% of our 20 patient samples significantly suppressed T cell proliferation (p<0.0001, sCAFs). Interestingly, cytokine secretion profiles of resting sCAFs revealed significantly elevated levels of inhibitory signaling compared to nCAFs (IL-13 p=0.001, M-CSF p<0.01, VEGF-A p=0.05, IL-8 p<0.01, IL-17 p<0.01, Eotaxin p<0.005). These results suggest that sCAFs in CRC, PDAC, and MM promote immune evasion and impair T cell activation and proliferation, but via distinct cytokine signaling.

We next assessed the effects of PDAC- or CRC-derived sCAFs and nCAFs on Claudin18.2 (CLDN18.2)-targeting CART cells in vivo. First, NSG mice were subcutaneously engrafted with a mixture of CLDN18.2+ SNU-C2B CRC cells and sCAFs or nCAFs (1x106 and 2.5x106 cells each). After tumor establishment, mice were treated with control T cells (UTD) or CLDN18.2-CART cells (5x106 cells). CLDN18.2-CART cells eliminated tumors in mice engrafted with nCAFs compared to UTD (p<0.0001) but failed to control tumor growth in mice engrafted with SNU-C2B and sCAFs. sCAF-engrafted mice exhibited significantly shorter survival compared to nCAF mice (85.7% survival reduction, Log-rank p=0.0002). Finally, we performed scRNAseq of our 20 patient-derived CAFs to study their molecular signatures. We identified 10 unique CAF clusters with increased abundance in sCAFs. Signature genes enriched in sCAF-rich clusters include CCL11 (log2FC= 8.26), IL6 (4.27), CSF1 (3.27), VEGFA (2.91), CD39 (2.54), CXCL12 (2.49), LGALS9 (1.53), CCL2 (1.35), and TGFB1 (0.96) (all adjusted p<0.0001).

In summary, we have identified FAP+ sCAFs as key drivers of CART cell therapeutic resistance in hematological and gastrointestinal cancers, supporting the integration of sCAF-targeting modalities to enhance CART cell efficacy in a broad array of cancers.

Omar Gutierrez-Ruiz, PhD: Immix - Patents & Royalties